ESR1 mutations (ESR1m) are a key driver of acquired endocrine resistance in HR+/HER2- advanced and metastatic breast cancer. ESR1m monitoring can detect ESR1m emergence in HR+/HER2- advanced breast cancer. For pathologists, a key consideration for testing is accurate detection of ESR1m using ctDNA-mediated (plasma) NGS or PCR assays (liquid biopsy).

Pathologists attending this 60-minute webinar will gain practical insight into how ctDNA-mediated ESR1m testing can help detect emerging endocrine resistance earlier, inform timely clinical decision-making, and support more effective collaboration with multidisciplinary care teams.

Learning Objectives 

Attending this session will enable learners to:

• Increase awareness of ctDNA-mediated ESR1m testing to detect emerging ET resistance
• Highlight the actionability of ctDNA-mediated ESR1m testing to detect ESR1m emergence in HR+/HER2- advanced breast cancer
• Discuss strategies for ESR1 mutation testing
• Encourage HCPs to advocate for ESR1 mutation testing with the MDT and tumor boards

The information presented represents the opinion of the presenter and is not necessarily the view of CAP Foundation. CAP Foundation does not endorse the products or services. The webinar is possible through a sponsorship from AstraZeneca. This activity is not available for CME.

Presenter

Mel Krystel-Whittemore, MD
Regional Medical Director, Medical Diagnostics, AstraZeneca

CAP, College of American Pathologists; CME, continuing medical education; ctDNA, circulating tumor DNA; ESR1m, estrogen receptor 1 mutation; ET, endocrine therapy; HCP, health care professional; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; MDT, multidisciplinary team; NGS, next-generation sequencing; PCR, polymerase chain reaction.

US-114567 Last Updated 8/26